Galapagos successfully completes placement of 2,125,925 new ordinary
shares
(Thomson Reuters ONE) - Proceeds used to accelerate clinical product development NOT FOR PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA.Mechelen, Belgium; 16 October 2009 - Galapagos NV (Euronext: GLPG)announces that it has successfully raised ?18.2 million through anaccelerated bookbuild offering of 2,125,925 new ordinary shares (the"Shares") at a price of ?8.55 per Share.Allocation of the Shares has taken place today with internationalinstitutional investors. Payment for and delivery of the Shares isexpected to take place on 21 October 2009, at which date the newlyissued Shares are expected to be admitted to listing on NYSE EuronextBrussels/Amsterdam. The number of 2,125,925 Shares represents justbelow 10% of the number of outstanding shares of the company on theday of the placement. Following issuance of the Shares, Galapagoswill have a total of 23,385,179 outstanding ordinary shares.The proceeds of the offering will be used to accelerate the clinicaldevelopment of Galapagos' candidate medicines, including next year'sPhase II clinical trial of GLPG0259 for rheumatoid arthritis.Fortis Bank Nederland / MeesPierson Corporate Finance & CapitalMarkets acted as Sole Global Coordinator and Sole Bookrunner for theoffering.About GalapagosGalapagos (Euronext: GLPG; OTC: GLPYY) is a drug discovery anddevelopment company with small molecule programs in bone and jointdiseases, bone metastasis, cachexia, anti-infectives and metabolicdiseases. It has established risk sharing alliances with GSK,Janssen Pharmaceutica, Eli Lilly and Merck and Co. Through analliance with MorphoSys, Galapagos is also developing new antibodytherapies in bone and joint diseases. Its division BioFocus DPIoffers a full suite of target-to-drug discovery products and servicesto pharmaceutical and biotech companies and to patient foundations,encompassing target discovery and validation, screening and drugdiscovery through to delivery of pre-clinical candidates. Galapagoscurrently employs 495 people and operates facilities in sixcountries, with global headquarters in Mechelen, Belgium. More infoat: www.glpg.com.CONTACTGalapagos NVOnno van de Stolpe, CEOTel: +31 6 2909 8028ir(at)glpg.comFortis Bank Nederland / MeesPierson Corporate Finance & CapitalMarketsSyndicationTel: +31 20 527 1709Cautionary note regarding forward-looking statementsThis release may contain forward-looking statements, including,without limitation, statements containing the words "believes,""anticipates," "expects," "intends," "plans," "seeks," "estimates,""may," "will," "could," and "continues," as well as similarexpressions. Such forward-looking statements may involve known andunknown risks, uncertainties and other factors which might cause theactual results, financial condition, performance or achievements ofGalapagos, or industry results, to be materially different from anyhistoric or future results, financial conditions, performance orachievements expressed or implied by such forward-lookingstatements. Given these uncertainties, the reader is advised not toplace any undue reliance on such forward-looking statements. Theseforward-looking statements speak only as of the date of publicationof this document. Galapagos expressly disclaims any obligation toupdate any such forward-looking statements in this document toreflect any change in its expectations with regard thereto or anychange in events, conditions or circumstances on which any suchstatement is based, unless required by law or regulation.The new shares have not been and will not be registered under the USSecurities Act of 1933, as amended (the "US Securities Act") and maynot be offered or sold in the United States absent registration or anexemption from registration. The Company does not intend to registerany portion of the Offering in the United States or to conduct apublic offering of securities in the United States.In relation to each member State of the European Economic Area whichhas implemented the Prospectus Directive (as defined below) (each, a"Relevant Member State"), with effect from and including the date onwhich the Prospectus Directive is implemented in that Relevant MemberState (the "Relevant Implementation Date"), the Offering will not bemade to the public in that Relevant Member State, except, with effectfrom and including the Relevant Implementation Date:(i) to qualified investors (as defined in the Prospectus Directive orimplementing legislation in the Relevant Member State) ("QualifiedInvestors");(ii) to fewer than 100 natural or legal persons (other than qualifiedinvestors as defined in the Prospectus Directive); or(iii) in any other circumstances which do not require the publicationby the Company of a prospectus pursuant to Article 3 of theProspectus Directive.For the purposes of this provision and when used elsewhere in thisannouncement, the expression an "offer of Shares to the public", orany similar expression, in relation to any Shares in any RelevantMember State means the communication in any form and by any means ofsufficient information on the terms of the Offering and the Shares tobe offered so as to enable an investor to decide to purchase orsubscribe for the Shares, as the same may be varied in that MemberState by any measure implementing the Prospectus Directive in thatMember State and the expression "Prospectus Directive" when used inthis announcement means Directive 2003/71/EC and includes anyrelevant implementing measure in each Relevant Member State.This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 16.10.2009 - 12:06 Uhr
Sprache: Deutsch
News-ID 6997
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 290 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Galapagos successfully completes placement of 2,125,925 new ordinary
shares"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
